Skip to content

Study · Randomized controlled trial · 2026

3 results

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Liu M, Cheng Z, Lu L, Cai H, Liu J, Liu J, Zheng Y, Wang S, Zhao J, Yang W, Xie T, Li Y, He A, Rodbard HW, Chen W

Annals of internal medicine30 Jun 2026

PMID42372276 (opens in a new tab)DOI10.7326/annals-25-04623 (opens in a new tab)PepBankPUB-42372276
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with type 2 diabetes, semaglutide 1 mg once weekly lowered HbA1c by 1.60% from baseline at week 24.

    In plain wordsIn Chinese adults with type 2 diabetes, semaglutide 1 mg weekly lowered HbA1c blood sugar marker over 24 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change from baseline at week 24
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg once weekly · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.6%
    semaglutide 1 mg QW

    Source sentences

    Summary
    -1.60% (CI, -1.85% to -1.35%) for 1 mg of semaglutide QW.
    2 context sentences
    Summary · context
    Adults with T2DM who were drug-naive or receiving stable oral antidiabetic drugs (glycated hemoglobin A1c [HbA1c], 7.0% to 11.0%).
    Summary · context
    Participants were randomly assigned 1:1:1:1:1 to 1 of 5 treatment groups: bofanglutide titrated to targets of 12, 18, or 24 mg (biweekly [once every 2 weeks; Q2W]); bofanglutide titrated to 24 mg (once weekly [QW]); or semaglutide titrated to 1 mg QW.
  2. 02HumanRandomized controlled trialSafety outcome

    In Chinese adults with type 2 diabetes, gastrointestinal adverse events occurred in 51.9% of participants on semaglutide, against 81.8% to 87.3% on bofanglutide.

    In plain wordsIn Chinese adults with type 2 diabetes, about half of those on semaglutide had stomach or gut side effects, fewer than with bofanglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Bofanglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1 mg once weekly · 24 weeksAs given in this study (human).

    Measurements

    GIAE incidence
    51.9%
    semaglutide 1 mg QW

    Source sentences

    Summary
    Gastrointestinal adverse events (GIAEs) (mostly grade 1 or 2 in severity) occurred in 81.8% to 87.3% and 51.9% of participants in the bofanglutide and semaglutide groups, respectively.
    2 context sentences
    Summary · context
    Adults with T2DM who were drug-naive or receiving stable oral antidiabetic drugs (glycated hemoglobin A1c [HbA1c], 7.0% to 11.0%).
    Summary · context
    Participants were randomly assigned 1:1:1:1:1 to 1 of 5 treatment groups: bofanglutide titrated to targets of 12, 18, or 24 mg (biweekly [once every 2 weeks; Q2W]); bofanglutide titrated to 24 mg (once weekly [QW]); or semaglutide titrated to 1 mg QW.
  3. 03HumanRandomized controlled trialSafety outcome

    In Chinese adults with type 2 diabetes, hypoglycemia occurred in 1.9% of participants on semaglutide, with no severe hypoglycemia.

    In plain wordsIn Chinese adults with type 2 diabetes, 1.9% on semaglutide had low blood sugar, and none had severe low blood sugar.

    Peptide
    Semaglutide
    Outcome
    Not applicableHypoglycemia
    Study

    n: not reported in source

    Comparator
    Bofanglutide
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1 mg once weekly · 24 weeksAs given in this study (human).

    Measurements

    Hypoglycemia incidence
    1.9%
    semaglutide 1 mg QW

    Source sentences

    Summary
    Hypoglycemia occurred in 0% to 3.8% versus 1.9%, with no severe hypoglycemia.
    2 context sentences
    Summary · context
    Adults with T2DM who were drug-naive or receiving stable oral antidiabetic drugs (glycated hemoglobin A1c [HbA1c], 7.0% to 11.0%).
    Summary · context
    Participants were randomly assigned 1:1:1:1:1 to 1 of 5 treatment groups: bofanglutide titrated to targets of 12, 18, or 24 mg (biweekly [once every 2 weeks; Q2W]); bofanglutide titrated to 24 mg (once weekly [QW]); or semaglutide titrated to 1 mg QW.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT06256549

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Gan and Lee Pharmaceuticals, USAn = 2729 Aug 2023 to est. 20 Jul 2024

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 23 Feb 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.